摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(Z)-7-[(1r,2r,3r,5s)-3,5-二羟基-2-((e)-(s)-3-羟基-5-苯基-1-戊烯)-环戊基]-5-庚烯酸甲酯 | 38315-47-8

中文名称
(Z)-7-[(1r,2r,3r,5s)-3,5-二羟基-2-((e)-(s)-3-羟基-5-苯基-1-戊烯)-环戊基]-5-庚烯酸甲酯
中文别名
比马前列素酸甲基酯
英文名称
(5Z)-methyl 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxy-5-phenylpent-1-enyl)cyclopentyl)hept-5-enoate
英文别名
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-((S)-(E)-3-hydroxy-5-phenylpent-1-enyl)-cyclopentyl]hept-5-enoic acid methyl ester;Bimatoprost acid methyl ester;methyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]hept-5-enoate
(Z)-7-[(1r,2r,3r,5s)-3,5-二羟基-2-((e)-(s)-3-羟基-5-苯基-1-戊烯)-环戊基]-5-庚烯酸甲酯化学式
CAS
38315-47-8
化学式
C24H34O5
mdl
——
分子量
402.531
InChiKey
UQBYFURYGYNQLQ-FDBOBMRISA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    557.2±50.0 °C(Predicted)
  • 密度:
    1.170±0.06 g/cm3(Predicted)
  • 溶解度:
    乙腈:3mg/mL; DMF:25mg/mL; DMSO:25mg/mL;乙醇:50mg/mL; PBS(pH 7.2):0.25 mg/mL

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    29
  • 可旋转键数:
    12
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    87
  • 氢给体数:
    3
  • 氢受体数:
    5

SDS

SDS:b57404fbe37a039e1451a4cee4710357
查看

制备方法与用途

比马前列素甲酯是比马前列腺素(HY-B0191)的前药。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PROCESS FOR THE PREPARATION OF BIMATOPROST<br/>[FR] PROCÉDÉ DE PRÉPARATION DE BIMATOPROST
    申请人:GENTEC S A
    公开号:WO2017182465A1
    公开(公告)日:2017-10-26
    It is provided a process for the preparation of bimatoprost, which comprises: a) reacting a compound of formula (III) with ethylamine in the presence of a suitable solvent; and b) deprotecting compound obtained in step a) to obtain bimatoprost, wherein R1 is selected from (C1-C16)alkyl, (C1C16)haloalkyl, (C2-C16)alkenyl, (C2-C16)haloalkenyl, (C1-C16)alkoxy(C1-C16)alkyl, aryl, (C1-C16)alkylaryl, allyl, - (CH2-CH2-O)n-CH3 wherein n = 1, 2, 3 or 4, and -CH(O-CH2-CH2)2; R2 is selected from H, (C1-C16)alkyl, (C1-C16)haloalkyl, (C2-C16)alkenyl, (C2- C16)haloalkenyl, (C1-C16)alkoxy(CrC16)alkyl, aryl, (C1-C16)alkylaryl, allyl; or, alternatively, R1 and R2 taken together are selected from -CH2-CH2-CH2-, -CH2-CH2-, -O-CH2-CH2-, and -O-CH=CH-. There are also provided intermediates useful in such preparation process.
    提供了一种制备比马前列素的方法,包括:a)在适当的溶剂存在下,将化合物(III)与乙胺发生反应;b)去保护步骤a)中得到的化合物,以获得比马前列素,其中R1选自(C1-C16)烷基,(C1-C16)卤代烷基,(C2-C16)烯基,(C2-C16)卤代烯基,(C1-C16)烷氧基(C1-C16)烷基,芳基,(C1-C16)烷基芳基,烯丙基,-(CH2- -O)n-CH3其中n = 1, 2, 3或4,和-CH(O- - )2;R2选自H,(C1-C16)烷基,(C1-C16)卤代烷基,(C2-C16)烯基,(C2-C16)卤代烯基,(C1-C16)烷氧基(C1-C16)烷基,芳基,(C1-C16)烷基芳基,烯丙基;或者,R1和R2一起选自- - - -,- - -,-O- - -,和-O-CH=CH-。还提供了在这种制备过程中有用的中间体。
  • PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS
    申请人:CHIROGATE INTERNATIONAL INC.
    公开号:US20150051410A1
    公开(公告)日:2015-02-19
    Novel processes for the preparation of a compound of Formula I-2 substantially free of the 5,6-trans isomer: wherein R 2 , R 3 and R 4 are as defined in the specification are provided. Novel intermediates for the preparations of isomer free Prostaglandins and derivatives thereof are also provided.
    提供了一种用于制备基本上不含5,6-顺式异构体的化合物I-2的新工艺:其中R2、R3和R4如规范中定义。还提供了用于制备无异构体前列腺素及其衍生物的新中间体。
  • Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
    申请人:Allergan Sales, Inc.
    公开号:US06359181B1
    公开(公告)日:2002-03-19
    The present invention provides a novel compound represented by the general formula I; wherein R is H or COR3; R1 is H, R2, phenyl, or COR3, wherein R2 is C1-C5 lower alkyl and R3 is R2 or phenyl; Z is CH2 or O; Y is OH, OCOR3 or ═O; x is 0 or 1; and X is C1-C5 n-alkyl, C3-C7 cycloalkyl, phenyl, furanyl, thienyl or substituted derivatives thereof, wherein the substituents maybe selected from the group consisting of C1-C5 alkyl, halogen, CF3, CN, NO2, NR42, CO2R4 and OR4 wherein R4 is hydrogen or C1-C5 alkyl and dotted lines represent the presence or absence of a double bond and wavy lines represent a cis or trans bond. These novel compounds are especially useful for treating elevated intraocular pressure (ocular hypertension) and glaucoma.
    本发明提供了一种新颖的化合物,其表示为通用式I;其中R为H或COR3;R1为H、R2、苯基或COR3,其中R2为C1-C5低碳烷基,R3为R2或苯基;Z为CH2或O;Y为OH、OCOR3或═O;x为0或1;X为C1-C5正烷基、C3-C7环烷基、苯基、呋喃基、噻吩基或其取代衍生物,其中取代基可能来自由C1-C5烷基、卤素、CF3、CN、NO2、NR42、CO2R4和OR4组成的群,其中R4为氢或C1-C5烷基,虚线表示双键的存在或缺失,波浪线表示顺式或反式键。这些新颖化合物特别适用于治疗高眼压(眼压升高)和青光眼。
  • Design and Synthesis of 13,14-Dihydro Prostaglandin F<sub>1α</sub> Analogues as Potent and Selective Ligands for the Human FP Receptor
    作者:Yili Wang、John A. Wos、Michelle J. Dirr、David L. Soper、Mitchell A. deLong、Glen E. Mieling、Biswanath De、Jack S. Amburgey、Eric G. Suchanek、Cynthia J. Taylor
    DOI:10.1021/jm990542v
    日期:2000.3.1
    selective ligands for the human prostaglandin F receptor (hFP receptor). The compounds lack the olefin unsaturation required for potency in the natural ligand PGF(2)(alpha) yet retain binding affinity for the hFP receptor in the nanomolar to micromolar range. Removal of the alkenes also results in a better selectivity ratio for the hFP receptor over the other prostaglandin receptors tested. A rationale
    描述了用于治疗骨质疏松症的新型潜在骨合成代谢药物的体外评估。这些化合物是人前列腺素F受体(hFP受体)的有效和选择性配体。该化合物缺乏天然配体PGF(2)α中效力所需的烯烃不饱和度,但在纳摩尔至微摩尔范围内仍保留了对hFP受体的结合亲和力。烯烃的去除还导致对hFP受体的选择性比所测试的其他前列腺素受体更好。还描述了基于与假定的hFP受体模型的配体对接实验,各种类似物的选择性差异的基本原理。
  • Bimatoprost crystalline form I
    申请人:Gutman Arie
    公开号:US20090163596A1
    公开(公告)日:2009-06-25
    The invention provides a novel polymorphic form I of crystalline bimatoprost, method for preparation thereof and new crystalline intermediates in the preparation. This form I of crystalline bimatoprost is used in purification of crude bimatoprost and in storage of bimatoprost as active pharmaceutical intermediate. Use of the physical form of bimatoprost in the manufacture of a medicament is also disclosed.
    本发明提供了一种新的多晶型I的晶体双滴眼液的制备方法,以及制备过程中的新晶体中间体。这种多晶型I的晶体双滴眼液可用于粗制双滴眼液的纯化和双滴眼液作为活性制药中间体的储存。本发明还揭示了在制造药物时使用双滴眼液的物理形式。
查看更多